What The Study Did: This study of 105 new drugs examined how often the Food and Drug Administration extrapolates the findings of a drug’s pivotal trial data to its approved indication in terms of disease severity, subtype or use with other medications. Extrapolation can lead to different clinical outcomes in practice than were observed in the pivotal trials.
Authors: Aaron S. Kesselheim, M.D., J.D., M.P.H., of Brigham and Women’s Hospital, Harvard Medical School in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.7958)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.7958?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=041922
About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open